×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Business Wire
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet...
1 hour ago
Kezar loses 41% of staff, CEO to keep lead lupus candidate on the road to phase 2 readout
Fierce Biotech
Kezar Life Sciences is significantly reducing both its workforce and pipeline to eke out cash over the years until its lead lupus drug reads...
7 months ago
Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
Yahoo Finance
SOUTH SAN FRANCISCO, Calif., March 14, 2024--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing...
1 month ago
Should You Sell Kezar Life Sciences Inc (KZR) Stock Thursday Morning?
InvestorsObserver
Kezar Life Sciences Inc (KZR) is up Thursday morning, with the stock rising 0.96% in pre-market trading to 1.05. KZR's short-term technical...
2 months ago
Kezar Life Sciences (NASDAQ:KZR) Trading Down 6.2%
MarketBeat
Kezar Life Sciences (NASDAQ:KZR) Stock Price Down 6.2%
3 weeks ago
Kezar Life Sciences reports Q4 EPS (44c), consensus (38c) - TipRanks.com
Tipranks
The efforts over the past year by the team at Kezar have put us in a strong position as we advance our promising, first-in-class immunology...
1 month ago
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus ...
Yahoo Finance
SHANGHAI & SOUTH SAN FRANCISCO, Calif., February 26, 2024--Everest Medicines (HKEX 1952.HK) and Kezar Life Sciences, Inc. (Nasdaq: KZR)...
2 months ago
Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference
Business Wire
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and...
2 months ago
Wells Fargo Downgrades Kezar Life Sciences
24/7 Wall St.
Wells Fargo Downgrades Kezar Life Sciences ... Fintel reports that on August 11, 2023, Wells Fargo downgraded their outlook for Kezar Life...
8 months ago
China's NMPA approves trial of treatment for lupus nephritis
Clinical Trials Arena
The Chinese NMPA has approved Kezar's application to begin the Phase IIb PALIZADE trial of zetomipzomib for lupus nephritis (LN).
2 months ago